| Tanja D Evans, MD | |
|
202 N Division St Ste 202, Auburn, WA 98001-4939 | |
| (253) 876-8088 | |
| Not Available |
| Full Name | Tanja D Evans |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 202 N Division St Ste 202, Auburn, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295777175 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD00044262 (Washington) | Primary |
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.
Researchers at the RIKEN-Max Planck Joint Research Center in Japan have demonstrated that hallmark symptoms of Alzheimer's disease can be reduced when sugars are prevented from binding to one of the key enzymes implicated in the disease. The new findings, reported in EMBO Molecular Medicine, show that abnormal attachment of a particular sugar to the enzyme BACE1 is a critical factor leading to the formation of Aβ plaques in the brain, and that plaques were reduced and cognitive performance improved when this action was prevented in mice through loss of the enzyme GnT-III.
PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.
Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.
In an important advance in the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified naturally occurring antibodies in human blood that may help to defend against this form of dementia as well as other neurodegenerative diseases.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tanja D Evans, MD 202 N Division St Ste 202, Auburn, WA 98001-4939 Ph: (253) 876-8088 | Tanja D Evans, MD 202 N Division St Ste 202, Auburn, WA 98001-4939 Ph: (253) 876-8088 |
News Archive
A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.
Researchers at the RIKEN-Max Planck Joint Research Center in Japan have demonstrated that hallmark symptoms of Alzheimer's disease can be reduced when sugars are prevented from binding to one of the key enzymes implicated in the disease. The new findings, reported in EMBO Molecular Medicine, show that abnormal attachment of a particular sugar to the enzyme BACE1 is a critical factor leading to the formation of Aβ plaques in the brain, and that plaques were reduced and cognitive performance improved when this action was prevented in mice through loss of the enzyme GnT-III.
PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.
Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.
In an important advance in the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified naturally occurring antibodies in human blood that may help to defend against this form of dementia as well as other neurodegenerative diseases.
› Verified 8 days ago
Bradley Thor Kuske, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 121 N Division St Ste 310, Auburn, WA 98001 Phone: 253-372-7121 | |
Beth W. Nauert, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 126 Auburn Ave Ste 300, Auburn, WA 98002 Phone: 537-350-1662 Fax: 253-833-8987 | |
Daniel Antonio Delgado, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 126 Auburn Ave Ste 300, Auburn, WA 98002 Phone: 253-735-0166 | |
Dr. Margarita Maria Guerra, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2709 V Ct Se, Auburn, WA 98002 Phone: 253-804-4065 | |
Varsha Raghavan, D.O Pediatrics Medicare: Medicare Enrolled Practice Location: 126 Auburn Ave Ste 300, Auburn, WA 98002 Phone: 253-735-0166 | |
Raymond R Myers, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 202 N Division St Ste 202, Auburn, WA 98001 Phone: 253-846-8088 Fax: 253-846-8079 |